We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
-19.3%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$82.8M
AUM Growth
-$28.8M
(-26%)
Cap. Flow
-$2.79M
Cap. Flow
% of AUM
-3.37%
Top 10 Holdings %
Top 10 Hldgs %
36.35%
Holding
122
New
10
Increased
23
Reduced
52
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CareDx
CDNA
|
+$930K |
| 2 |
Gilead Sciences
GILD
|
+$732K |
| 3 |
BEAT
BioTelemetry, Inc.
BEAT
|
+$704K |
| 4 |
Alphatec Holdings
ATEC
|
+$579K |
| 5 |
Rockwell Medical
RMTI
|
+$577K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aflac
AFL
|
+$1.02M |
| 2 |
Microvision
MVIS
|
+$808K |
| 3 |
The Joint Corp
JYNT
|
+$802K |
| 4 |
CEMI
Chembio diagnostics, Inc.
CEMI
|
+$780K |
| 5 |
ANI Pharmaceuticals
ANIP
|
+$709K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.87% |
| 2 | Technology | 10.8% |
| 3 | Communication Services | 7.03% |
| 4 | Industrials | 5.89% |
| 5 | Consumer Staples | 4.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Champions Oncology
CSBR
$72.7M
| $152K | 0.18% |
20,500
-17,500
| -46% | -$122K |
|
77
Apyx Medical
APYX
$171M
| $151K | 0.18% |
42,200
-300
| -0.7% | -$2.01K |
|
78
Veritone
VERI
$122M
| $148K | 0.18% |
63,566
-218,467
| -77% | -$542K |
|
|
TYME
79
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
| $134K | 0.16% |
122,250
-18,750
| -13% | -$25.2K |
|
80
Option Care Health
OPCH
$3.61B
| $123K | 0.15% |
13,000
-2,125
| -14% | -$31.2K |
|
|
MNDT
81
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $119K | 0.14% |
11,211
-600
| -5% | -$8.63K |
|
|
ZIXI
82
DELISTED
Zix Corporation
ZIXI
| $108K | 0.13% |
25,000
| – | – |
|
83
Digi International
DGII
$3.15B
| $103K | 0.12% |
+10,800
| New | +$150K |
|
84
Airgain
AIRG
$74.9M
| $100K | 0.12% |
13,500
-2,000
| -13% | -$17.4K |
|
85
IRIDEX
IRIX
$14.6M
| $100K | 0.12% |
63,100
+9,500
| +18% | +$24.5K |
|
|
ASXC
86
DELISTED
Asensus Surgical, Inc.
ASXC
| $79K | 0.1% |
+224,117
| New | +$234K |
|
87
TELA Bio
TELA
$38.9M
| $78K | 0.09% |
10,000
| – | – |
|
|
AMRN
88
Amarin Corp
AMRN
$304M
| $70K | 0.08% |
870
-155
| -15% | -$51.5K |
|
|
FOCL
89
EDAP TMS S.A.
FOCL
$228M
| $57K | 0.07% |
25,000
| – | – |
|
|
MOBL
90
DELISTED
MobileIron, Inc.
MOBL
| $55K | 0.07% |
14,500
| – | – |
|
|
IMDX
91
Insight Molecular Diagnostics
IMDX
$156M
| $53K | 0.06% |
+1,086
| New | +$53.2K |
|
92
Traws Pharma
TRAW
$8.08M
| $48K | 0.06% |
+427
| New | +$67K |
|
|
ATHX
93
DELISTED
Athersys, Inc. Common Stock
ATHX
| $42K | 0.05% |
560
-360
| -39% | -$12.7K |
|
94
Senseonics Holdings Inc
SENS
$350M
| $41K | 0.05% |
3,250
+175
| +6% | +$3.52K |
|
|
AGRX
95
DELISTED
Agile Therapeutics
AGRX
| $40K | 0.05% |
+11
| New | +$63.1K |
|
|
NVIV
96
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
| $35K | 0.04% |
833
-667
| -44% | -$94.4K |
|
97
Energy Focus
EFOI
$20.2M
| $29K | 0.04% |
+2,509
| New | +$46.9K |
|
|
SIEN
98
DELISTED
Sientra, Inc.
SIEN
| $27K | 0.03% |
+1,350
| New | +$70.5K |
|
99
CarParts.com
PRTS
$52.6M
| $25K | 0.03% |
1,450
| – | – |
|
|
CTEK
100
DELISTED
CynergisTek, Inc.
CTEK
| $21K | 0.03% |
15,000
| – | – |
|
Similar funds
PWP
BF
WT
BAM
WLG
STFP
SWM
9C
Perkins Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Perkins Capital Management held 122 positions worth $82.8M, down 26% from $112M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Perkins Capital Management withdrew a net $2.79M in Q1 2020, closing 15 positions and reducing 52 holdings. Its most notable exit was Aflac, an estimated $1.02M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 63% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Perkins Capital Management opened a new position in Gilead Sciences worth $792K.
- Perkins Capital Management's largest Q1 2020 buy was Gilead Sciences: 10,600 shares worth $792K.
- Perkins Capital Management added most to CareDx in Q1 2020, an estimated $930K increase.
- Perkins Capital Management's biggest Q1 2020 reduction was Veritone, cutting an estimated $542K.
- Perkins Capital Management fully exited Aflac in Q1 2020, selling an estimated $1.02M.
- Perkins Capital Management's ten largest holdings make up 36% of its $82.8M portfolio in Q1 2020.
- Perkins Capital Management opened 10 new positions and closed 15 in Q1 2020.
- Perkins Capital Management's portfolio value fell 26% quarter-over-quarter to $82.8M.
Based on Perkins Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.